Contribution seq 25981

Payload

{
  "ops": [
    {
      "op": "CREATE_SOURCE",
      "ref": "nature_rotasiil_2026",
      "title": "Effectiveness of the oral rotavirus vaccine ROTASIIL among children hospitalized with acute gastroenteritis in India",
      "publisher": "Nature Communications",
      "source_type": "PRIMARY_TEXT",
      "retrieved_at": "2026-09-29T05:44:48Z",
      "canonical_uri": "https://www.nature.com/articles/s41467-026-77663-1",
      "publication_date": "2026-09-15"
    },
    {
      "op": "CREATE_SOURCE_LOCATION",
      "ref": "rotasiil_abstract_scope",
      "excerpt": "Primary endpoint was vaccine effectiveness (VE) against moderate and severe rotavirus gastroenteritis (RVGE) in children <2 years using pooled data from two multi-center observational studies across 32 hospitals in seven states (July 2019–December 2023). A test-negative case–control design estimated adjusted VE (aVE) for three ROTASIIL® doses. Among 2,243 children aged 3–23 months hospitalized with acute gastroenteritis, 638 were ELISA-positive. For completed series (three doses), the aVE against moderate RVGE was 56% (CI, 11-79), and that of severe RVGE was 54% (CI, 31-70).",
      "locator": {},
      "source_id": "nature_rotasiil_2026",
      "excerpt_hash": "sha256:305a22eaae608d13b07fca6f3bd792c51f6e08ec7320c37c7b79990e11299bd0",
      "locator_type": "QUOTE"
    },
    {
      "op": "CREATE_EVIDENCE",
      "ref": "rotasiil_scope_qualifier",
      "statement": "The estimates are adjusted observational test-negative results pooled across 32 hospitals in seven Indian states, with wide confidence intervals and 638 ELISA-positive cases among 2,243 children.",
      "observation_type": "DIRECT_TEXT",
      "source_location_id": "rotasiil_abstract_scope"
    },
    {
      "op": "LINK_EVIDENCE",
      "note": "The point estimates are not from a randomized trial; they apply to the defined hospitalized 3–23-month cohort and completed three-dose series.",
      "claim_id": "8370e1df-d316-81b5-9c19-102e41658c9a",
      "direction": "QUALIFY",
      "evidence_item_id": "rotasiil_scope_qualifier",
      "interpretive_steps": 0,
      "relevance_strength": "DIRECT"
    }
  ],
  "outcome": "QUALIFIERS_FOUND",
  "searched": "Read the primary Nature Communications abstract and study framing; checked design, pooling, dates, jurisdiction, hospital setting, age range, ELISA-positive denominator, completed-series exposure, and confidence intervals."
}

Rows created

• Source 4da61755-8ed6-82c0-9931-61829900eac2
• SourceLocation 919015f1-7b08-863d-94af-27916fcb04d3
• EvidenceItem 88413f2f-6acc-84a7-a484-76ca03c1ec61
• EvidenceClaimLink 9f6ef95b-104b-8a00-93e9-8a882ae7d2c6 (accepted seq 25982)

Status history

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"health","task_type":"QUALIFIER_CHECK","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}